Search for a trial

Brightline-1: A Phase II/III, randomized, openlabel, multi-center study of brigimadlin (BI
907828) compared to doxorubicin as first line treatment of patients with advanced
dedifferentiated liposarcoma.

This study has been transitioned to CTIS with ID 2024-511361-11-00 check the CTIS register for the current data. The trial will assess the efficacy and safety of brigimadlin compared to doxorubicin as first line systemic therapy for advanced or…